Method of treating diabetes type 2 by administering ultrarapid acting insulin

Patent metadata

Field	Value
Publication number	US-2024197836-A1
Application number	US-202418593204-A
Country	US
Kind code	A1
Filing date	Mar 1, 2024
Priority date	Aug 11, 2008
Publication date	Jun 20, 2024
Grant date	—

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

First claim

What is claimed is:

1 . A method of improving post-prandial blood glucose homeostasis in an overweight patient with type 2 diabetes currently being treated with a suppressor of hepatic glucose output, said method comprising:
administering an ultrarapid acting insulin (URAI) preparation with at least one established meal; wherein said treatment results in weight loss or reduced weight gain as compared to treatment with a suppressor of hepatic glucose output alone.

2 . The method of claim 1 , wherein said URAI preparation is administered by inhalation.

3 . The method of claim 2 , wherein said URAI preparation comprises a dry powder.

4 . The method of claim 3 , wherein said URAI preparation comprises 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine wherein X is one of succinyl, glutaryl, maleyl and fumaryl; or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , wherein X is fumaryl.

6 . The method of claim 5 , wherein said insulin comprises human insulin.

7 . The method of claim 6 , wherein said human insulin comprises recombinant insulin.

8 . The method of claim 7 , wherein said dry powder is crystalline.

9 . The method of claim 6 , wherein said suppressor of hepatic glucose output comprises metformin.

12 . The method of claim 8 , wherein said crystalline dry powder is provided in a cartridge.

13 . The method of claim 12 , wherein said cartridge comprises 4, 8, or 12 units of insulin.

14 . The method of claim 12 , wherein said crystalline dry powder is administered using an inhaler.

15 . The method of claim 1 , wherein said treatment results in weight loss as compared to treatment with a suppressor of hepatic glucose output alone.

16 . The method of claim 1 , wherein said treatment results in reduced weight gain as compared to treatment with a suppressor of hepatic glucose output alone.

17 . The method of claim 1 , further comprising administration of a GLP-1 agonist.

Assignees

• Mannkind Corp

Inventors

• Richardson Peter
• Baughman Robert A
• Potocka Elizabeth
• Boss Anders Hasager
• Petrucci Richard

Classifications

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61K9/0021

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

• A61K47/545

  Heterocyclic compounds (A61K47/558 takes precedence) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title